Table of Content

1    Market
1.1    Product Definition
1.1.1    Inclusion and Exclusion
1.2    Market Scope
1.2.1    Scope of the Study
1.2.2    Key Questions Answered in the Report
1.3    Market Overview
1.3.1    Introduction
1.3.2    Types of Hematologic Malignancies Diagnostic Tests
1.3.3    Market Footprint and Growth Potential
2    Market Dynamics
2.1    Overview
2.2    Impact Analysis
2.3    Market Drivers
2.3.1    Rising Incidence in Hematologic Malignancies
2.3.1.1    New Cases
2.3.1.2    Deaths
2.3.2    Increasing Key Player Initiatives
2.3.3    Growing Funding in the Market for Hematologic Malignancies Testing
2.4    Market Restraints
2.4.1    Lack of Qualified Professionals
2.4.2    Issues Concerning the Analytical Validity of Cancer Genetic Testing
2.5    Market Opportunities
2.5.1    Increasing Research and Development Activities
2.5.2    Technological Advancements in the Field of Hematologic Malignancies Testing
2.6    Industry Analysis
2.6.1    Regulatory Framework
2.6.2    Regulatory Framework in the U.S.
2.6.3    Regulatory Framework in Europe
2.6.4    Regulatory Framework in Asia-Pacific
2.6.4.1    Japan
2.6.4.2    China
2.7    COVID-19's Impact on Cancer Diagnostic Market
2.7.1    Disruption in Global Hematologic Malignancies Testing Market Due to COVID-19
2.7.2    Effect of COVID-19 on Cancer Medicine and Science
2.7.3    Effect on Workforce and Research Funding
2.7.4    Effect on Cancer Screening
2.7.5    Future of Cancer Beyond COVID-19 in Medicine and Science
2.7.5.1    Implementation of Telemedicine
2.8    Supply Chain Analysis
2.8.1    Key Entities in Supply Chain
2.9    Pricing Analysis
2.9.1    Pricing Analysis By Platform Testing
2.1    Comparative Analysis of Hematologic Malignancies Test by Different Parameters
3    Competitive Landscape
3.1    Overview
3.2    Synergistic Activities
3.3    Product Launches
3.4    Product Approvals
3.5    Mergers and Acquisitions
3.6    Other Business Activities
3.7    Market Share Analysis (by Company), 2020 and 2021
3.8    Growth-Share Analysis (by Platform)
4    Products
4.1    Overview
4.1.1    Kits
4.1.1.1    Gene Panels
4.1.1.2    Molecular Clonality Testing
4.1.1.3    Translocation Testing
4.1.1.4    Mutation Testing
4.1.1.5    Minimal Residual Disease (MRD) Testing
4.1.2    Services
5    Platform
5.1    Overview
5.1.1    Next-Generation Sequencing (NGS)
5.1.2    Polymerase Chain Reaction (PCR)
5.1.3    Fluorescence In-Situ Hybridization (FISH)
5.1.4    Immunohistochemistry (IHC)
5.1.5    Flow Cytometry
5.1.6    Other Platforms
5.1.6.1    Cytogenetic Testing
5.1.6.2    Microarray
6    Diseases
6.1    Overview
6.2    Leukemia
6.3    Lymphoma
6.4    Multiple Myeloma
6.5    Myeloproliferative Neoplasms
6.6    Myelodysplastic Syndromes
7    End User
7.1    Overview
7.2    Specialty Clinics and Hospitals
7.3    Diagnostic Laboratories
7.4    Reference Laboratories
7.5    Research Institutions
8    Region
8.1    Overview
8.2    North America
8.2.1    U.S.
8.2.2    Canada
8.3    Europe
8.3.1    Germany
8.3.2    France
8.3.3    U.K.
8.3.4    Italy
8.3.5    Spain
8.3.6    Denmark
8.3.7    Rest-of-Europe
8.4    Asia-Pacific
8.4.1    China
8.4.2    Japan
8.4.3    India
8.4.4    South Korea
8.4.5    Australia
8.4.6    Singapore
8.4.7    Rest-of-Asia-Pacific
8.5    Latin America
8.5.1    Brazil
8.5.2    Mexico
8.5.3    Rest-of-Latin America
8.6    Rest-of-the-World
9    Market - Company Profiles
9.1    Overview
9.2    Abbott.
9.2.1    Company Overview
9.2.2    Role of Abbott. in the Global Hematologic Malignancies Testing Market
9.2.3    Key Competitors of the Company
9.2.4    Key Customers of the Company
9.2.5    Corporate Strategies
9.2.6    Financials
9.2.7    Key Insights about the Financial Health of the Company
9.2.8    Analyst Perspectives
9.3    ASURAGEN, INC.
9.3.1    Company Overview
9.3.2    Role of ASURAGEN, INC. in the Global Hematologic Malignancies Testing Market
9.3.3    Key Competitors of the Company
9.3.4    Key Customers of the Company
9.3.5    Analyst Perspectives
9.4    Adaptive Biotechnologies
9.4.1    Company Overview
9.4.2    Role of Adaptive Biotechnologies in the Global Hematologic Malignancies Testing Market
9.4.3    Key Competitors of the Company
9.4.4    Key Customers of the Company
9.4.5    Corporate Strategies
9.4.6    Financials
9.4.7    Key Insights about the Financial Health of the Company
9.4.8    Analyst Perspectives
9.5    ARUP Laboratories
9.5.1    Company Overview
9.5.2    Role of ARUP Laboratories in the Global Hematologic Malignancies Testing Market
9.5.3    Key Competitors of the Company
9.5.4    Key Customers of the Company
9.5.5    Analyst Perspectives
9.6    Bio-Rad Laboratories, Inc.
9.6.1    Company Overview
9.6.2    Role of Bio-Rad Laboratories, Inc. in the Global Hematologic Malignancies Testing Market
9.6.3    Key Competitors of the Company
9.6.4    Key Customers of the Company
9.6.5    Financials
9.6.6    Key Insights about the Financial Health of the Company
9.6.7    Analyst Perspectives
9.7    F. Hoffmann-La Roche Ltd
9.7.1    Company Overview
9.7.2    Role of F. Hoffmann-La Roche Ltd in the Global Hematologic Malignancies Testing Market
9.7.3    Key Competitors of the Company
9.7.4    Key Customers of the Company
9.7.5    Corporate Strategies
9.7.6    Business Strategies
9.7.7    Financials
9.7.8    Key Insights about the Financial Health of the Company
9.7.9    Analyst Perspectives
9.8    Illumina, Inc.
9.8.1    Company Overview
9.8.2    Role of Illumina, Inc. in the Global Hematology Malignancies Testing Market
9.8.3    Key Competitors of the Company
9.8.4    Key Customers of the Company
9.8.5    Corporate Strategies
9.8.6    Financials
9.8.7    Key Insights about the Financial Health of the Company
9.8.8    Analyst Perspectives
9.9    ICON plc
9.9.1    Company Overview
9.9.2    Role of ICON plc in the Global Hematologic Malignancies Testing Market
9.9.3    Key Competitors of the Company
9.9.4    Key Customers of the Company
9.9.5    Financials
9.9.6    Analyst Perspectives
9.1    Invivoscribe, Inc.
9.10.1    Company Overview
9.10.2    Role of Invivoscribe, Inc. in the Global Hematologic Malignancies Testing Market
9.10.3    Key Competitors of the Company
9.10.4    Key Customers of the Company
9.10.5    Analyst Perspectives
9.11    Invitae Corporation.
9.11.1    Company Overview
9.11.2    Role of Invitae Corporation. in the Global Hematologic Malignancies Testing Market
9.11.3    Key Competitors of the Company
9.11.4    Key Customers of the Company
9.11.5    Corporate Strategies
9.11.6    Financials
9.11.7    Key Insights about the Financial Health of the Company
9.11.8    Analyst Perspectives
9.12    Laboratory Corporation of America Holdings
9.12.1    Company Overview
9.12.2    Role of Laboratory Corporation of America Holdings in the Global Hematologic Malignancies Testing Market
9.12.3    Key Competitors of the Company
9.12.4    Key Customers of the Company
9.12.5    Corporate Strategies
9.12.6    Financials
9.12.7    Analyst Perspectives
9.13    NeoGenomics Laboratories
9.13.1    Company Overview
9.13.2    Role of NeoGenomics Laboratories in the Global Hematologic Malignancies Testing Market
9.13.3    Key Competitors of the Company
9.13.4    Key Customers of the Company
9.13.5    Financials
9.13.6    Key Insights about the Financial Health of the Company
9.13.7    Analyst Perspectives
9.14    OHSU’s Knight Diagnostic Laboratories
9.14.1    Company Overview
9.14.2    Role of OHSU’s Knight Diagnostic Laboratories in the Global Hematologic Malignancies Testing Market
9.14.3    Key Competitors of the Company
9.14.4    Key Customers of the Company
9.14.5    Analyst Perspectives
9.15    Precipio
9.15.1    Company Overview
9.15.2    Role of Precipio in the Global Hematologic Malignancies Testing Market
9.15.3    Key Competitors of the Company
9.15.4    Key Customers of the Company
9.15.5    Corporate Strategies
9.15.6    Business Strategies
9.15.7    Financials
9.15.8    Analyst Perspectives
9.16    QIAGEN N.V.
9.16.1    Company Overview
9.16.2    Role of QIAGEN N.V. in the Global Hematologic Malignancies Testing Market
9.16.3    Key Competitors of the Company
9.16.4    Key Customers of the Company
9.16.5    Corporate Strategies
9.16.6    Financials
9.16.7    Key Insights about the Financial Health of the Company
9.16.8    Analyst Perspectives
9.17    Quest Diagnostics
9.17.1    Company Overview
9.17.2    Role of Quest Diagnostics in the Global Hematologic Malignancies Testing Market
9.17.3    Key Competitors of the Company
9.17.4    Key Customers of the Company
9.17.5    Corporate Strategies
9.17.6    Financials
9.17.7    Analyst Perspectives
9.18    Sysmex Corporation
9.18.1    Company Overview
9.18.2    Role of Sysmex Corporation in the Global Hematologic Malignancies Testing Market
9.18.3    Key Competitors of the Company
9.18.4    Key Customers of the Company
9.18.5    Business Strategies
9.18.6    Financials
9.18.7    Key Insights about the Financial Health of the Company
9.18.8    Analyst Perspectives
List of Figures    
Figure 1:    Estimated Hematologic Malignancies Cases
Figure 2:    Impact Analysis of Market Drivers and Market Challenges on the Global Hematologic Malignancies Testing Market
Figure 3:    Global Hematologic Malignancies Testing Market (by Product), $Million, 2021 and 2032
Figure 4:    Global Hematologic Malignancies Testing Market (by Platform), $Million, 2021 and 2032
Figure 5:    Global Hematologic Malignancies Testing Market (by Disease), $Million, 2021 and 2032
Figure 6:    Global Hematologic Malignancies Testing Market (by End User), $Million, 2021 and 2032
Figure 7:    Global Hematologic Malignancies Testing Market
Figure 8:    Global Hematologic Malignancies Testing Market: Research Methodology
Figure 9:    Primary Research Methodology
Figure 10:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 11:    Global Hematologic Malignancies Testing Market Segmentation
Figure 12:    Classification of Hematologic Malignancies
Figure 13:    Global Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 14:    Blood Cancer Cases, 2021 (% Share)
Figure 15:    Workflow for the Product Approval in the Market
Figure 16:    Workflow for the IVD Product Approval
Figure 17:    Workflow for Medical Device Regulations
Figure 18:    Workflow for Market Approval of In-Vitro Diagnostics in China
Figure 19:    COVID-19 Poses Several Concerns for Patients, Health Care Providers, and Health Systems
Figure 20:    Global Hematologic Malignancies Testing Market: COVID-19 Impact Analysis
Figure 21:    Medical Research Cycle Interruption during the COVID-19 Pandemic
Figure 22:    Telemedicine's Potential Advantages
Figure 23:    Hematologic Malignancies Testing Supply Chain Analysis
Figure 24:    Share of Key Developments and Strategies, January 2018-May 2022
Figure 25:    Share of Synergistic Activities (by Company), January 2018-May 2022
Figure 26:    Number of Product Launches (by Company), January 2018-May 2022
Figure 27:    Share of Product Approval (by Company), January 2018-May 2022
Figure 28:    Share of Mergers and Acquisitions (by Company), January 2018-May 2022
Figure 29:    Share of other business activities (by Company), January 2018-May 2022
Figure 30:    Market Share Analysis of Global Hematologic Malignancies Testing Market (by Company), 2020 and 2021
Figure 31:    Growth-Share Analysis for Global Hematologic Malignancies Testing Market (by Platform), 2021
Figure 32:    Segmentation of Hematologic Malignancies Testing Market
Figure 33:    Share of Global Hematologic Malignancies Market (by Product), $Million, 2021 and 2032
Figure 34:    Global Hematologic Malignancies Testing Market (by Kits)
Figure 35:    Global Hematologic Malignancies Testing Market (Kits), $Million, 2021-2032
Figure 36:    Global Hematologic Malignancies Testing Market (Kits), Thousand Units, 2021-2032
Figure 37:    Global Hematologic Malignancies Testing Market (Gene Panels), $Million, 2021-2032
Figure 38:    Global Hematologic Malignancies Testing Market (Gene Panels), Thousand Units, 2021-2032
Figure 39:    Global Hematologic Malignancies Testing Market (Molecular Clonality Testing), $Million, 2021-2032
Figure 40:    Global Hematologic Malignancies Testing Market (Molecular Clonality Testing), Thousand Units, 2021-2032
Figure 41:    Company Offering Translocation Panel for Leukemia
Figure 42:    Global Hematologic Malignancies Testing Market (Translocation Testing), $Million, 2021-2032
Figure 43:    Global Hematologic Malignancies Testing Market (Translocation Testing), Thousand Units, 2021-2032
Figure 44:    Companies Offering Mutation Testing Kits
Figure 45:    Global Hematologic Malignancies Testing Market (Mutation Testing), $Million, 2021-2032
Figure 46:    Global Hematologic Malignancies Testing Market (Mutation testing), Thousand Units, 2021-2032
Figure 47:    Global Hematologic Malignancies Testing Market (Minimal Residual Disease (MRD) Testing), $Million, 2021-2032
Figure 48:    Global Hematologic Malignancies Testing Market (Minimal Residual Disease (MRD) Testing), Thousand Units, 2021-2032
Figure 49:    Global Hematologic Malignancies Testing Market (Services), $Million, 2021-2032
Figure 50:    Global Hematologic Malignancies Testing Market (Services), Thousand Units, 2021-2032
Figure 51:    Global Hematologic Malignancies Testing Market (by Platform)
Figure 52:    Share of Global Hematologic Malignancies Testing Market (by Platform), $Million, 2021 and 2032
Figure 53:    Benefits of NGS for Clinical Diagnostics and Biomarker Testing in Oncology
Figure 54:    Global Hematologic Malignancies Testing Market (Next-Generation Sequencing (NGS)), $Million, 2021-2032
Figure 55:    Global Hematologic Malignancies Testing Market (Next-Generation Sequencing), Thousand Units, 2021-2032
Figure 56:    Global Hematologic Malignancies Testing Market (Polymerase Chain Reaction (PCR)), $Million, 2021-2032
Figure 57:    Global Hematologic Malignancies Testing Market (Polymerase Chain Reaction (PCR)), Thousand Units, 2021-2032
Figure 58:    Global Hematologic Malignancies Testing Market (Fluorescence In-Situ Hybridization (FISH)), $Million, 2021-2032
Figure 59:    Global Hematologic Malignancies Testing Market (Fluorescence In-Situ Hybridization (FISH)), Thousand Units, 2021-2032
Figure 60:    Global Hematologic Malignancies Testing Market (Immunohistochemistry (IHC)), $Million, 2021-2032
Figure 61:    Global hematologic malignancies testing Market (Immunohistochemistry), Thousand Units, 2021-2032
Figure 62:    Global Hematologic Malignancies Testing Market (Flow Cytometry), $Million, 2021-2032
Figure 63:    Global Hematologic Malignancies Testing Market (Flow Cytometry), Thousand Units, 2021-2032
Figure 64:    Global Hematologic Malignancies Testing Market (Other Platforms), $Million, 2021-2032
Figure 65:    Global Hematologic Malignancies Testing Market (Other Platforms), Thousand Units, 2021-2032
Figure 66:    Share of Global Hematologic Malignancies Testing Market (by Disease), $Million, 2021 and 2032
Figure 67:    Global Hematologic Malignancies Testing Market (Leukemia), $Million, 2021-2032
Figure 68:    Global Hematologic Malignancies Testing Market (Lymphoma), $Million, 2021-2032
Figure 69:    Global Hematologic Malignancies Testing Market (Multiple Myeloma), $Million, 2021-2032
Figure 70:    Global Hematologic Malignancies Testing Market (Myeloproliferative Neoplasms), $Million, 2021-2032
Figure 71:    Global Hematologic Malignancies Testing Market (Myelodysplastic Syndromes), $Million, 2021-2032
Figure 72:    Share of Global Hematologic Malignancies Testing Market (by End User), $Million, 2021 and 2032
Figure 73:    Global Hematologic Malignancies Testing Market (Specialty Clinics and Hospitals), $Million, 2021-2032
Figure 74:    Global Hematologic Malignancies Testing Market (Specialty Clinics and Hospitals), Thousand Units, 2021-2032
Figure 75:    Global Hematologic Malignancies Testing Market (Diagnostic Laboratories), $Million, 2021-2032
Figure 76:    Global Hematologic Malignancies Testing Market (Diagnostic Laboratories), Thousand Units, 2021-2032
Figure 77:    Global Hematologic Malignancies Testing Market (Reference Laboratories), $Million, 2021-2032
Figure 78:    Global Hematologic Malignancies Testing Market (Reference Laboratories), Thousand Units, 2021-2032
Figure 79:    Global Hematologic Malignancies Testing Market (Research Institutions), $Million, 2021-2032
Figure 80:    Global Hematologic Malignancies Testing Market (Research Institutions), Thousand Units, 2021-2032
Figure 81:    Global Hematologic Malignancies Testing Market Snapshot (by Region), $Million, 2021-2032
Figure 82:    Global Hematologic Malignancies Testing Market (by Region), $Million, 2021-2032
Figure 83:    North America Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 84:    North America: Market Dynamics
Figure 85:    North America Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 86:    North America Hematologic Malignancies Testing Market, Thousand Units, 2022-2032
Figure 87:    U.S. Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 88:    U.S. Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 89:    U.S. Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 90:    U.S. Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 91:    U.S. Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 92:    U.S. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 93:    Canada Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 94:    Canada Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 95:    Canada Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 96:    Canada Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 97:    Canada Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 98:    Canada Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 99:    Europe Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 100:    Europe Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 101:    Europe: Market Dynamics
Figure 102:    Europe Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 103:    Germany Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 104:    Germany Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 105:    Germany Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 106:    Germany Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 107:    Germany Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 108:    Germany Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 109:    France Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 110:    France Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 111:    France Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 112:    France Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 113:    France Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 114:    France Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 115:    U.K. Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 116:    U.K. Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 117:    U.K. Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 118:    U.K. Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 119:    U.K. Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 120:    U.K. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 121:    Italy Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 122:    Italy Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 123:    Italy Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 124:    Italy Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 125:    Italy Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 126:    U.S. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 127:    Spain Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 128:    Spain Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 129:    Spain Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 130:    Spain Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 131:    Spain Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 132:    Spain Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 133:    Denmark Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 134:    Denmark Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 135:    Denmark Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 136:    Denmark Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 137:    Denmark Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 138:    Denmark Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 139:    Rest-of-Europe Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 140:    Rest-of-Europe Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 141:    Rest-of-Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 142:    Rest-of-Europe Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 143:    Rest-of Europe Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 144:    Rest-of-Europe Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 145:    Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 146:    Asia-Pacific Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 147:    Asia-Pacific: Market Dynamics
Figure 148:    Asia-Pacific Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 149:    China Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 150:    China Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 151:    China Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 152:    China Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 153:    China Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 154:    China Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 155:    Japan Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 156:    Japan Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 157:    Japan Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 158:    Japan Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 159:    Japan Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 160:    Japan Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 161:    India Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 162:    India Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 163:    India Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 164:    India Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 165:    India Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 166:    India Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 167:    South Korea Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 168:    South Korea Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 169:    South Korea Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 170:    South Korea Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 171:    South Korea Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 172:    South Korea Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 173:    Australia Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 174:    Number of Death in Australia by Leukemia (2012-2017)
Figure 175:    Australia Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 176:    Australia Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 177:    Australia Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 178:    Australia Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 179:    Australia Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 180:    Singapore Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 181:    Singapore Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 182:    Singapore Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 183:    Singapore Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 184:    Singapore Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 185:    Singapore Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 186:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 187:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 188:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 189:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 190:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 191:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 192:    Latin America Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 193:    Latin America Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 194:    Latin America: Market Dynamics
Figure 195:    Latin America Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 196:    Brazil Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 197:    Brazil Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 198:    Brazil Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 199:    Brazil Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 200:    Brazil Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 201:    Brazil Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 202:    Mexico Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 203:    Mexico Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 204:    Mexico Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 205:    Mexico Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 206:    Mexico Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 207:    Mexico Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 208:    Rest-of-Latin America Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 209:    Rest-of-Latin America Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 210:    Rest-of-Latin America Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 211:    Rest-of-Latin America Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 212:    Rest-of-Latin America Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 213:    Rest-of-Latin America Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 214:    Rest-of-the-World Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 215:    Rest-of-the-World Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 216:    Total Number of Companies Profiled
Figure 217:    Abbott.: Overall Product Portfolio
Figure 218:    Abbott.: Overall Financials, $Million, 2019-2021
Figure 219:    Abbott.: Revenue (by Segment), $Million, 2019-2021
Figure 220:    Abbott.: Revenue (by Region), $Million, 2019-2021
Figure 221:    Abbott.: R&D Expenditure, $Million, 2019-2021
Figure 222:    ASURAGEN, INC.: Overall Product Portfolio
Figure 223:    Adaptive Biotechnologies: Overall Product Portfolio
Figure 224:    Adaptive Biotechnologies: Overall Financials, $Million, 2019-2021
Figure 225:    Adaptive Biotechnologies: Revenue (by Segment), $Million, 2019-2021
Figure 226:    Adaptive Biotechnologies: R&D Expenditure, $Million, 2019-2021
Figure 227:    ARUP Laboratories: Overall Product Portfolio
Figure 228:    Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 229:    Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 230:    Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 231:    Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 232:    Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 233:    F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 234:    F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 235:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 236:    F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
Figure 237:    F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 238:    Illumina, Inc.: Overall Product Portfolio
Figure 239:    Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 240:    Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 241:    Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 242:    Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 243:    ICON plc: Overall Product Portfolio
Figure 244:    ICON plc: Overall Financials, $Million, 2019-2021
Figure 245:    ICON plc: Revenue (by Region), $Million, 2019-2021
Figure 246:    Invivoscribe, Inc.: Overall Product Portfolio
Figure 247:    Invitae Corporation.: Overall Product Portfolio
Figure 248:    Invitae Corporation.: Overall Financials, $Million, 2019-2021
Figure 249:    Invitae Corporation.: Revenue (by Segment), $Million, 2019-2021
Figure 250:    Invitae Corporation.: Revenue (by Region), $Million, 2019-2021
Figure 251:    Invitae Corporation.: R&D Expenditure, $Million, 2019-2021
Figure 252:    Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 253:    Laboratory Corporation of America Holdings: Overall Financials, $Million, 2019-2021
Figure 254:    Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2019-2021
Figure 255:    Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2019-2021
Figure 256:    NeoGenomics Laboratories: Overall Product Portfolio
Figure 257:    NeoGenomics Laboratories: Overall Financials, $Million, 2019-2021
Figure 258:    NeoGenomics Laboratories: Revenue (by Segment), $Million, 2019-2021
Figure 259:    NeoGenomics Laboratories: R&D Expenditure, $Million, 2019-2021
Figure 260:    OHSU’s Knight Diagnostic Laboratories: Overall Product Portfolio
Figure 261:    Precipio: Overall Product Portfolio
Figure 262:    Precipio: Overall Financials, $Million, 2019-2021
Figure 263:    Precipio: Revenue (by Segment), $Million, 2019-2021
Figure 264:    QIAGEN N.V.: Overall Product Portfolio
Figure 265:    QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 266:    QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
Figure 267:    QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
Figure 268:    QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
Figure 269:    Quest Diagnostics: Overall Product Portfolio
Figure 270:    Quest Diagnostics: Overall Financials, $Million, 2019-2021
Figure 271:    Quest Diagnostics: Revenue (by Segment), $Million, 2019-2021
Figure 272:    Sysmex Corporation: Overall Product Portfolio
Figure 273:    Sysmex Corporation: Overall Financials, $Million, 2018-2020
Figure 274:    Sysmex Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 275:    Sysmex Corporation: Revenue (by Region), $Million, 2018-2020
Figure 276:    Sysmex Corporation: R&D Expenditure, $Million, 2018-2020
List of Tables    
Table 1:    Diagnostic Tests for Hematologic Malignancies
Table 2:    Likert Scale
Table 3:    Impact Analysis of Market Drivers
Table 4:    Impact Analysis of Market Restraints
Table 5:    Registration Criteria for IVDs as per the CFDA
Table 6:    Effect of COVID-19 on Cancer Care Throughout the World
Table 7:    Companies Offering Gene Panels
Table 8:    Companies Offering Services
Table 9:    NGS-Based Products
Table 10:    PCR-Based Products
Table 11:    Companies Offering FISH-Based Products
Table 12:    Companies Offering IHC-Based Products
Table 13:    Company Offering Flow Cytometry-Based Product
Table 14:    Estimated Cases of Leukemia, by Gender, 2021
Table 15:    Companies Offering Leukemia Testing Products
Table 16:    Estimated Cases of Lymphoma, by Gender, 2021
Table 17:    Companies Offering Lymphoma Testing Products
Table 18:    Estimated Cases of Myeloma, by Gender, 2021
Table 19:    Companies Offering Multiple Myeloma Products